Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Subviral Agents01:29

Subviral Agents

550
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
550
Air-entraining Agents01:27

Air-entraining Agents

264
Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
264
Masking and Demasking Agents01:19

Masking and Demasking Agents

3.5K
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.5K
Nursing Clinical Information System01:27

Nursing Clinical Information System

1.3K
Nursing Clinical Information System (NCIS)
A Nursing Clinical Information System (NCIS) is a specialized type of healthcare information system tailored to meet the unique needs of nursing practice. It incorporates the principles of nursing informatics to streamline information management and improve the quality of care delivery.
Critical attributes of NCIS include:
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

618
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
618
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.3K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Science translational medicine·2026
Same author

Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.

Blood cancer journal·2026
Same author

Persistent <i>BCR::ABL1</i>-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

HemaSphere·2026
Same author

Ultra-high-sensitivity next-generation sequencing-based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort.

Blood cancer journal·2026
Same author

Comprehensive mutational profiling and clinical outcome of adult acute myeloid leukemia patients with NUP98 rearrangement.

Leukemia·2026
Same author

Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.

Leukemia·2026

Related Experiment Video

Updated: Jan 25, 2026

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K

Clinical update on hypomethylating agents.

Matthieu Duchmann1,2, Raphael Itzykson3,4

  • 1INSERM/CNRS UMR 944/7212, Saint-Louis Research Institute, Paris Diderot University, Paris, France.

International Journal of Hematology
|April 26, 2019
PubMed
Summary

Hypomethylating agents (HMAs) like azacitidine are standard treatments for high-risk myelodysplastic syndromes and acute myeloid leukemia. Future progress relies on new HMA compounds and combination therapies.

Keywords:
Acute myeloid leukemiaChronic myelomonocytic leukemiaHypomethylating agentsMyelodysplastic syndromesMyeloid malignancies

More Related Videos

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.5K
An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C
11:53

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C

Published on: June 1, 2018

7.0K

Related Experiment Videos

Last Updated: Jan 25, 2026

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time
06:05

The Participant-Reported Implementation Update and Score PRIUS: A Novel Method for Capturing Implementation-Related Data Over Time

Published on: February 19, 2021

1.6K
Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.5K
An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C
11:53

An Alternative Culture Method to Maintain Genomic Hypomethylation of Mouse Embryonic Stem Cells Using MEK Inhibitor PD0325901 and Vitamin C

Published on: June 1, 2018

7.0K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Hypomethylating agents (HMAs), including azacitidine and decitabine, are established treatments for higher-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in patients unsuitable for intensive chemotherapy.
  • Despite their established role, the precise molecular and cellular mechanisms of HMAs are still under investigation.
  • Current research has not yet identified reliable biomarkers to predict HMA response.

Purpose of the Study:

  • To review the current understanding of HMA mechanisms in myeloid neoplasms.
  • To highlight the limitations in predicting clinical efficacy and the need for biomarkers.
  • To discuss future directions for improving HMA therapy.

Main Methods:

  • Literature review of research on hypomethylating agents in myeloid neoplasms.
  • Analysis of current clinical applications and limitations of HMAs.
  • Exploration of ongoing and future therapeutic strategies involving HMAs.

Main Results:

  • The clinical efficacy of HMAs in myeloid neoplasms is confirmed but modest.
  • Biomarker discovery for HMA therapy has not yet yielded robust results.
  • Understanding HMA mechanisms remains an active area of research.

Conclusions:

  • Further advancements in HMA therapy will likely stem from developing next-generation, orally available agents with enhanced pharmacokinetic profiles.
  • Identifying synergistic drug combinations with HMAs, though often empirical, is crucial for improving clinical outcomes.
  • Optimizing HMA use across different disease stages and patient populations is essential.